Drug intelligence / Profile preview

ZR202-CoV + ZR202a-CoV

Development stage: Unknown
Lead developer: Shanghai Zerun Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ZR202-CoV + ZR202a-CoV is a combination of two human monoclonal antibodies developed by Beijing Zhihe Biopharma for the treatment of COVID-19. Both antibodies are designed to target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. By binding to distinct or overlapping epitopes on the RBD, the cocktail prevents the virus from interacting with the human angiotensin-converting enzyme 2 (ACE2) receptor, thereby neutralizing the virus and blocking its entry into host cells. This dual-antibody approach is intended to enhance potency and maintain efficacy against emerging viral variants that might escape neutralization by a single antibody.

Other names: ZR202-CoV/ZR202a-CoV cocktail

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on ZR202-CoV + ZR202a-CoV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZR202-CoV + ZR202a-CoV.

Explore the full profile